EUVIMEDEUVIMED entdecken
Crossref

Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade

Eric P Grewal, Leland G K Richardson, Jing Sun, Rishab Ramapriyan, Maria Martinez-Lage, Julie J Miller, Daniel P Cahill, Bryan D Choi, William T Curry

Neurosurgical Focus · 2024

DOI: 10.3171/2023.11.focus23694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurosurgical Focus, 2024. Verfasst von Eric P Grewal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departments of1Neurosurgery. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma, Glioblastoma, Astrocytoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: NCI NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Several studies have compared the immune microenvironment of isocitrate dehydrogenase (IDH)–wildtype glioma versus IDH-mutant glioma. The authors sought to determine whether histological tumor progression in a subset of IDH-mutant glioma was associated with concomitant alterations in the intratumoral immune microenvironment. METHODS The authors performed bulk RNA sequencing on paired and unpaired samples from patients with IDH-mutant glioma who underwent surgery for tumor progression across multiple timepoints. They compared patterns of differential gene expression, overall inflammatory signatures, and transcriptomic measures of relative immune cell proportions. RESULTS A total of 55 unique IDH-mutant glioma samples were included in the analysis. The authors identified multiple genes associated with progression and higher grade across IDH-mutant oligodendrogliomas and astrocytomas. Compared with lower-grade paired samples, grade 4 IDH-mutant astrocytomas uniquely demonstrated upregulation of VEGFA in addition to counterproductive alterations in inflammatory score reflective of a more hostile immune microenvironment. CONCLUSIONS Here, the authors have provided a transcriptomic analysis of a progression cohort for IDH-mutant glioma. Compared with lower-grade tumors, grade 4 astrocytomas displayed alterations that may inform the timing of antiangiogenic and immune-based therapy as these tumors progress.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsGliomaGlioblastomaAstrocytomaHumansIsocitrate DehydrogenaseUp-RegulationMutationTumor MicroenvironmentVascular Endothelial Growth Factor A

Stichwörter der Autor:innen

cancer microenvironmentimmunomodulatory therapyisocitrate dehydrogenase 1malignant gliomasmyeloid cellstranscriptome profiling

Substanzen

Isocitrate DehydrogenaseVEGFA protein, humanVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Departments of1Neurosurgery.
  • 2Pathology, and.
  • 3Neurology, Massachusetts General Hospital, Boston, Massachusetts.

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Grewal, E. P., Richardson, L. G. K., Sun, J., Ramapriyan, R., Martinez-Lage, M., Miller, J. J., Cahill, D. P., Choi, B. D., & Curry, W. T. (2024). Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade. Neurosurgical Focus. https://doi.org/10.3171/2023.11.focus23694

Vancouver

Grewal EP, Richardson LGK, Sun J, Ramapriyan R, Martinez-Lage M, Miller JJ, et al. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade. Neurosurgical Focus. 2024. doi:10.3171/2023.11.focus23694

BibTeX
@article{Grewal2024,
  author = {Grewal, Eric P and Richardson, Leland G K and Sun, Jing and Ramapriyan, Rishab and Martinez-Lage, Maria and Miller, Julie J and Cahill, Daniel P and Choi, Bryan D and Curry, William T},
  title = {Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade},
  journal = {Neurosurgical Focus},
  year = {2024},
  doi = {10.3171/2023.11.focus23694}
}
Kostenlos starten →